Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.

Date publication

juillet 2021

Journal

Targeted oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Callejo A, Faouzi S, Bouché O, Bertucci F, Chevalier T, Isambert N, Duffaud F, Collard O, Penel N, Terrier P, Mir O, Blay JY, Le Cesne A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34089444

Résumé

Retrospective analyses suggest that patients with advanced KIT exon 9-mutated gastrointestinal stromal tumors (GISTs) receiving imatinib 800 mg (rather than 400 mg) daily have better outcomes. In the adjuvant setting, the question of the optimal dose of imatinib remains unsettled.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Exons, genetics, Female, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, pharmacology, Male, Middle Aged, Mutation, Protein Kinase Inhibitors, pharmacology, Retrospective Studies, Young Adult

Référence

Target Oncol. 2021 07;16(4):485-492